Oncology

Sygnature Discovery will be presenting a workshop at ELRIG UK’s Drug Discovery 2021 event entitled, Gaining a career in industry: Learning tips and tricks from the inside. It will take place on the first day of Drug Discovery 2021 in Liverpool, from 10.50 – 11.50am in Room 11B.  This workshop will be led by Allan Jordan, Director […]

Crown Bioscience has launched its ‘3D Ex Vivo Patient Tissue Platform’ which, using freshly collected patient tumour material, can accurately measure oncology and immuno-oncology drug-induced tumour killing and endogenous immune cell proliferation in a high throughput format.   Researchers presented data on the new platform at 2021’s AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which took place virtually on October 7-10, 2021.  […]

Mount Sinai researchers have developed a therapy that shows promise against a fatal paediatric leukaemia. The small-molecule therapy was highly effective in fighting a type of acute myeloid leukaemia in both in vitro and in vivo experiments, according to research published in Science Translational Medicine in September 2021. The therapy, named MS67, causes the degradation of the WDR5 protein, […]

Researchers have discovered a potential advancement in the treatment of chronic myeloid leukaemia (CML), which they hope will one day offer an improved option for treating patients with this form of blood cancer. The study– published in Science Translational Medicine and led by the University of Glasgow in collaboration with LifeArc – has discovered a […]

Cancer is a complex disease that continuously evolves in response to environmental pressures. The dynamism and heterogeneity of tumours have significant clinical implications. In this eBook, Mission Bio reviews how single-cell DNA sequencing and multi-omics are used to dissect clonal architecture, providing valuable insights for clinical strategies, therapeutic resistance, disease modelling, and the development of […]

Results from a Phase III trial show promise for patients with advanced breast cancer. Enhertu has been shown to reduce the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support Enhertu as the potential new standard […]

Qingyun Liu, leader of a preclinical development core where researchers can test the effectiveness of large molecule drug candidates for novel cancer treatments, has been awarded an approximately $4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).  Liu is Professor of Precision Biomedicine with the Brown Foundation Institute of Molecular Medicine for […]

Nottingham, UK-based contract research organisation (CRO) Cellomatics Biosciences has reported year-on-year organic revenue growth of 30% since its inception in 2015, as demand for its preclinical and early discovery phase laboratory services and expertise continues to increase.   Based at BioCity Nottingham, Cellomatics is a specialist preclinical CRO with expertise in five main therapeutic areas: oncology, immuno-oncology, immunology, inflammation and respiratory. Despite the challenges […]

Australian clinical-stage drug development company Noxopharm has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate Covid-19 disease. Veyonda currently has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and […]

Avacta has appointed Dr Fiona McLaughlin as Chief Scientific Officer of its therapeutics division, effective immediately. Dr McLaughlin is an experienced oncology drug developer, bringing over 25 years’ experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical development. Dr McLaughlin started her […]